A review on clinical, pathological characteristics and drug designing for COVID-19
Arab Journal of Basic and Applied Sciences
; 28(1):172-186, 2021.
Article
in English
| Scopus | ID: covidwho-1246672
ABSTRACT
In late 2019, a novel strain of coronavirus (2019-nCoV) named as severe respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, a city in China, through some zoonotic reservoir, most probably a bat, and spread throughout the world. There have been around 22,213,869 reported cases of COVID-19 and almost 781,677 deaths worldwide according to the data updated by World Health Organization till 20 August 2020. It transmitted via droplets from an infected person to a healthy person in a very short duration of time. After the completion of the incubation period, which ranges from 2 to 14 days, the person experiences pneumonia-like symptoms such as fever, sore throat, cough, breathlessness, malaise, fatigue, and multi-organ dysfunction, etc. The main receptor of SARS-CoV-2 is angiotensin-converting enzyme 2 which binds with the spike (S) protein of the virus and helps it in attachment and entry to the host cells. COVID-19 is diagnosed by molecular testing of respiratory secretions and CT scan analysis. Because of the absence of any approved treatment options for COVID-19, a number of research studies are being carried out to find out any combination of already approved drugs or new lead compounds using in silico docking and screening strategies. © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of the University of Bahrain.
Full text:
Available
Collection:
Databases of international organizations
Database:
Scopus
Type of study:
Prognostic study
Language:
English
Journal:
Arab Journal of Basic and Applied Sciences
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS